Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Other Operating Expenses (2023 - 2025)

Iovance Biotherapeutics has reported Other Operating Expenses over the past 7 years, most recently at $52.6 million for Q4 2025.

  • Quarterly results put Other Operating Expenses at $52.6 million for Q4 2025, down 55.23% from a year ago — trailing twelve months through Dec 2025 was $206.5 million (up 4.66% YoY), and the annual figure for FY2025 was $209.1 million, up 59.82%.
  • Other Operating Expenses for Q4 2025 was $52.6 million at Iovance Biotherapeutics, up from $47.5 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for IOVA hit a ceiling of $117.4 million in Q4 2024 and a floor of $2.0 million in Q2 2023.
  • Median Other Operating Expenses over the past 3 years was $41.2 million (2024), compared with a mean of $38.8 million.
  • Biggest five-year swings in Other Operating Expenses: soared 1430.15% in 2024 and later tumbled 55.23% in 2025.
  • Iovance Biotherapeutics' Other Operating Expenses stood at $16.1 million in 2023, then soared by 631.04% to $117.4 million in 2024, then tumbled by 55.23% to $52.6 million in 2025.
  • The last three reported values for Other Operating Expenses were $52.6 million (Q4 2025), $47.5 million (Q3 2025), and $56.7 million (Q2 2025) per Business Quant data.